Midostaurin: an emerging treatment for acute myeloid leukemia patients

References

• SiegelRLMillerKDJemalACancer statistics, 2015CA Cancer J Clin201565152925559415
   PubMed Web of Science ®Google Scholar
• SanzMBurnettALo-CocoFLowenbergBFLT3 inhibition as a targeted therapy for acute myeloid leukemiaCurr Opin Oncol200921659460019684517
   PubMed Web of Science ®Google Scholar
• WeisbergEBoultonCKellyLMInhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412Cancer Cell20021543344312124173
   PubMed Web of Science ®Google Scholar
• WhitmanSPArcherKJFengLAbsence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B studyCancer Res200161197233723911585760
   PubMed Web of Science ®Google Scholar
• FrohlingSSchlenkRFBreitruckJPrognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group UlmBlood2002100134372438012393388
   PubMed Web of Science ®Google Scholar
• SchlenkRFDohnerKKrauterJMutations and treatment outcome in cytogenetically normal acute myeloid leukemiaN Engl J Med2008358181909191818450602
   PubMed Web of Science ®Google Scholar
• KayserSSchlenkRFLondonoMCInsertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcomeBlood2009114122386239219602710
   PubMed Web of Science ®Google Scholar
• RockovaVAbbasSWoutersBJRisk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markersBlood201111841069107621596848
   PubMed Web of Science ®Google Scholar
• PatelJPGonenMFigueroaMEPrognostic relevance of integrated genetic profiling in acute myeloid leukemiaN Engl J Med2012366121079108922417203
   PubMed Web of Science ®Google Scholar
• FabbroDBuchdungerEWoodJInhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agentPharmacol Ther1999822–329330110454207
   PubMed Web of Science ®Google Scholar
• FabbroDRuetzSBodisSPKC412 – a protein kinase inhibitor with a broad therapeutic potentialAnticancer Drug Des2000151172810888033
   PubMedGoogle Scholar
• PratzKWSatoTMurphyKMStineARajkhowaTLevisMFLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AMLBlood201011571425143220007803
   PubMed Web of Science ®Google Scholar
• WilliamsCBKambhampatiSFiskusWPreclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemiaPharmacotherapy201333121341135223798029
   PubMed Web of Science ®Google Scholar
• McDonaldACPopperDKingDChampainKGrafPManAPhase I and pharmacokinetic study of CGP 41521, an inhibitor of protein kinase (abstract)Proc Am Soc Clin Oncol199715212a
   Google Scholar
• WangYYinOQGrafPKisickiJCSchranHDose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitusJ Clin Pharmacol200848676377518508951
   PubMed Web of Science ®Google Scholar
• PropperDJMcDonaldACManAPhase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase CJ Clin Oncol20011951485149211230495
   PubMed Web of Science ®Google Scholar
• StoneRMDeAngeloDJKlimekVPatients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412Blood20051051546015345597
   PubMed Web of Science ®Google Scholar
• StratiPKantarjianHRavandiFPhase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndromeAm J Hematol201590427628125530214
   PubMed Web of Science ®Google Scholar
• YinOQWangYSchranHA mechanism-based population pharmacokinetic model for characterizing time-dependent pharmacokinetics of midostaurin and its metabolites in human subjectsClin Pharmacokinet2008471280781619026036
   PubMed Web of Science ®Google Scholar
• StoneRMFischerTPaquetteRPhase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemiaLeukemia20122692061206822627678
   PubMed Web of Science ®Google Scholar
• ZarrinkarPPGunawardaneRNCramerMDAC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)Blood2009114142984299219654408
   PubMed Web of Science ®Google Scholar
• DutreixCMunariniFLorenzoSRoeselJWangYInvestigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteersCancer Chemother Pharmacol20137261223123424085261
   PubMed Web of Science ®Google Scholar
• FischerTStoneRMDeangeloDJPhase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3J Clin Oncol201028284339434520733134
   PubMed Web of Science ®Google Scholar
• CooperBWKindwall-KellerTLCraigMDA phase I study of midostaurin and azacitidine in relapsed and elderly AML patientsClin Lymphoma Myeloma Leuk2015157428432e42225776192
   PubMed Web of Science ®Google Scholar
• Stone RMMSSanfordBLGeyerSThe multi-kinase inhibitor midostaurin (M) prolongs survival compared with placebo (P) in combination with daunorubicin (D)/cytarabine (C) induction (ind), high-dose C consolidation (consol), and as maintenance (maint) therapy in newly diagnosed acute myeloid leukemia (AML) patients (pts) age 18–60 with FLT3 mutations (muts): An international prospective randomized (rand) P-controlled double-blind trial (CALGB 10603/RATIFY [Alliance]) (abstract)Paper presented at: American Society of Hematology (ASH) 57th Annual MeetingDecember 3–6, 2015Orlando, FL, USA
   Google Scholar
• Corces-ZimmermanMRMajetiRPre-leukemic evolution of hematopoietic stem cells: the importance of early mutations in leukemogenesisLeukemia201428122276228225005245
   PubMed Web of Science ®Google Scholar
• DohnerHWeisdorfDJBloomfieldCDAcute myeloid leukemiaN Engl J Med2015373121136115226376137
   PubMed Web of Science ®Google Scholar
• StolzelFSteudelCOelschlagelUMechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cellsAnn Hematol201089765366220119833
   PubMed Web of Science ®Google Scholar
• HeidelFSolemFKBreitenbuecherFClinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domainBlood2006107129330016150941
   PubMed Web of Science ®Google Scholar
• GiriSHamdehSBhattVRSchwarzJKSorafenib in relapsed AML with FMS-like receptor tyrosine kinase-3 internal tandem duplication mutationJ Natl Compr Canc Netw201513550851425964636
   PubMed Web of Science ®Google Scholar
• ServeHKrugUWagnerRSorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trialJ Clin Oncol201331253110311823897964
   PubMed Web of Science ®Google Scholar
• LeungAYManCHKwongYLFLT3 inhibition: a moving and evolving target in acute myeloid leukaemiaLeukemia201327226026822797419
   PubMed Web of Science ®Google Scholar
• SudhindraASmithCCFLT3 inhibitors in AML: are we there yet?Curr Hematol Malig Rep20149217418524682858
   PubMed Web of Science ®Google Scholar
• GrunwaldMRLevisMJFLT3 tyrosine kinase inhibition as a paradigm for targeted drug development in acute myeloid leukemiaSemin Hematol201552319319926111466
   PubMed Web of Science ®Google Scholar
• KiyoiHFlt3 inhibitors: recent advances and problems for clinical applicationNagoya J Med Sci2015771–271725797966
   PubMed Web of Science ®Google Scholar
• CortesJEKantarjianHForanJMPhase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication statusJ Clin Oncol201331293681368724002496
   PubMed Web of Science ®Google Scholar
• Levis MJPAAltmanJKCortesJEResults of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) (Abstr 7003)J Clin Oncol201533 abstr 7003
   Google Scholar
• ZimmermanEITurnerDCBuaboonnamJCrenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemiaBlood2013122223607361524046014
   PubMed Web of Science ®Google Scholar
• ThomCPreliminary data on ASP2215: tolerability and efficacy in acute myeloid leukemia patientsFuture Oncol201511182499250126279055
   PubMed Web of Science ®Google Scholar
• LevisMJ PADombretHDohnerHFinal results of a phase 2 open-label, monotherapy efficacy and safety study of quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory myeloid leukemia after second-line chemotherapy or hematopoietic stem cell transplantationBlood2012120673
   Google Scholar